Title

The Serum Angiotensin-converting Enzyme 2 and Angiotensin-(1-7) Concentrations after Optimal Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction

Shinji Hisatake, MD, PhD; Shunsuke Kiuchi, MD, PhD; Takayuki Kabuki, MD, PhD; Takashi Oka, MD; Shintaro Dobashi, MD; Takahiro Fujii, MD; Takanori Ikeda, MD, PhD

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan

Correspondence address:
Shinji Hisatake, MD, PhD
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine
6-11-1 Omorinashi, Ota-ku, Tokyo 143-8541, Japan
Telephone: +81-3-3762-4151, Fax: +81-3-3766-3271, E-mail: s-hisata@td5.so-net.ne.jp

Number of Tables: 4; Number of Figures: 4
Number of Supplementary files: 0
Abstract

Objective: Elucidation of the role of angiotensin-converting enzyme (ACE)2/angiotensin (Ang)-(1-7)/Mas receptor axis in heart failure is necessary. No previous study has reported serial changes in ACE2 and Ang-(1-7) concentrations after optimal therapy (OP) in acute heart failure (AHF) patients. We aimed to investigate serial changes in serum ACE2 and Ang-(1-7) concentrations after OP in AHF patients with reduced ejection fraction (EF).

Methods: ACE2 and Ang-(1-7) concentrations were measured in 68 AHF patients with reduced EF immediately after admission and 1 and 3 months after OP. These parameters were compared with the healthy individuals at three time points.

Results: In the acute phase, Ang-(1-7) and ACE2 concentrations was statistically significantly lower and higher in AHF patients than the healthy individuals (2.40±1.11 vs. 3.1±1.1 ng/mL, P<0.005 and 7.45±3.13 vs. 4.84±2.25 ng/mL, P<0.005, respectively). At 1 month after OP, Ang-(1-7) concentration remained lower in AHF patients than the healthy individuals (2.37±1.63 vs. 3.1±1.1 ng/mL, P<0.05); however, there was no statistically significant difference in ACE2 concentration between AHF patients and the healthy individuals. At 3 months after OP, there were no statistically significant differences in Ang-(1-7) and ACE2 concentrations between AHF patients and the healthy individuals.

Conclusion: ACE2 concentration was equivalent between AHF patients and the healthy individuals at months 1 and 3 after OP, and Ang-(1-7) concentration was equivalent at months 3 after OP.

Key Words: Angiotensin-converting enzyme 2; Angiotensin-(1-7); Acute heart failure; Optimal therapy
**Introduction**

Studies have shown that the renin–angiotensin system (RAS) is associated with worsening of hypertension and various types of organopathies via the angiotensin-converting enzyme (ACE)/angiotensin (Ang) II/Ang II type 1 receptor axis [1,2]. Long-term activation of the neurohormonal response, especially of the sympathetic nervous system and the renin-angiotensin-aldosterone system, is a major molecular hallmark of adverse LV remodeling. In fact, the levels of both plasma catecholamines and aldosterone are important predictors of cardiovascular mortality in post-MI patients [3,4].

Recent studies have established the existence of a new cascade in the RAS called the ACE2/Ang-(1-7)/Mas receptor axis [5,6]. Ang-(1-7) is a degradation product of Ang I and Ang II associated with ACE2. Studies in mice have reported that Ang-(1-7) stimulates the Mas receptor and induces hypotensive effects and organ-protective effects primarily through vasodilation, natriuresis, regulation of myocardial hypertrophy and anti-inflammation [7-12]. Therefore, Ang-(1-7) has antagonistic influences on the effects induced by the Ang II type 1 receptor.

We previously reported that acute heart failure (AHF) patients requiring hospitalisation had higher serum ACE2 and lower Ang-(1-7) concentrations in the acute phase when compared to the concentrations in healthy volunteers [13]. Furthermore, it is very interesting to evaluate the variability of serum ACE2 and Ang-(1-7) concentrations in the process of compensating for heart failure. However, no study has reported serial changes in serum ACE2 and Ang-(1-7) concentrations after optimal therapy in these patients. Because of serum ACE2 and Ang-(1-7) concentrations may be biomarkers that reflect the pathogenesis of heart failure, significance of measuring ACE2 and Ang-(1-7)
concentrations in patients with compensated heart failure, is very important. The present study aimed to investigate the serial changes in the serum ACE2 and Ang-(1-7) concentrations after optimal therapy in AHF patients requiring inpatient care.

Also, due to the recent worldwide pandemic of COVID-19, investigation regarding role of ACE2 has been in the limelight.

Materials and methods

Study design

Among patients who were urgently admitted to our hospital because of AHF with reduced left ventricular ejection fraction (LVEF) between November 2012 and September 2015, we enrolled 68 patients who consented to participate in this study and were followed for at least 3 months. AHF was diagnosed according to the Framingham criteria [14]. Patients received optimal drug therapy according to previous guidelines [15], during hospitalisation and after discharge as outpatients.

The exclusion criteria were as follows: 1) LVEF is over 40 %; 2) age <20 years; 3) need for mechanical support; 4) renal failure (serum creatinine level >3.0 mg/dL); 5) pregnancy, possible pregnancy, nursing and desire to become pregnant during the study period; and 6) judgement as inappropriate for this study by responsible doctors.

The patients were treated in accordance with the Declaration of Helsinki after obtaining informed consent. The study protocol was approved by the Ethics Committee of Toho University Omori Hospital, Japan (application number 25-229).

Primary endpoints
The reference values of serum ACE 2 and Ang-(1-7) concentrations have not been established so far. Therefore, the value of the concentrations in healthy volunteers [13] was defined as the healthy individuals. The primary endpoints of this study were the serum Ang-(1-7) and ACE2 concentrations at 1 month later and 3 months later after optimal therapy in the patients were compared with the healthy individuals.

**Blood sampling**

Upper limb venous blood samples were percutaneously collected while AHF patients maintained the sitting posture for more than 30 min after they became capable of sitting in the acute phase. Similarly, upper limb venous blood samples were percutaneously collected 1 and 3 months after optimal therapy for heart failure while the patients maintained the sitting posture for more than 30 min.

The serum ACE2 concentration, Ang-(1-7) concentration plasma aldosterone concentration and plasma brain natriuretic peptide (BNP) concentration were measured. The reagents and detailed method for each test are described in past report [13]. Additionally, serum ACE2 and Ang-(1-7) concentrations at three time points were compared with the healthy individuals, which have been reported previously [13].

After collection, all blood samples were immediately centrifuged at 3000 rpm for 10 min in our laboratory. Dispensed specimens were frozen in dry ice. On the day of blood collection, specimens were brought to LSI Medience Corporation and were preserved in a deep freezer until measurement. ACE2 was measured without specimen dilution, and Ang-(1-7) was measured after diluting the specimen five times. With regard to cross reactivity, we did not perform enzyme treatment, but all blood samples were immediately frozen. Serum ACE2 and Ang 1-7 concentrations were measured
using ELISA kits (Peninsula Laboratories, LLC, San Carlos, CA), according to the manufacturer’s instructions, except for solid phase extraction (SPE). We did not extract Ang-(1-7) from serum samples using SPE. After blood separation, all experiments were performed at LSI Medience Corporation using the following kits: ACE2 (Cat. No. AG-45A-0022EK-KI01; Adipogen, San Diego, CA) and Ang-(1-7) (Cat. No. S-1330 Angiotensin I/II (1-7); Peninsula Laboratories, LLC).

Echocardiographic measurements

Transthoracic echocardiography was performed using echocardiograph on admission (in resting conditions). Two dimensional imaging was performed in standard apical views. The LVEF was measured by Simpson method. Two experienced cardiologists unaware of the biochemical data performed the echocardiographic measurements.

Statistical analysis

All data are expressed as mean ± standard deviation (SD). Serial changes in the plasma aldosterone concentration and BNP concentration were analysed using one-way analysis of variance (ANOVA). For the serum ACE2 concentration and Ang-(1-7) concentration, values at baseline, 1 month later and 3 months later were analysed using the unpaired Student’s t-test and were compared to the healthy individuals, which were reported previously [13]. The unpaired Student’s t-test and ANOVA were performed using SPSS software (ver. 20.0; IBM Corp., Armonk, NY). Statistical significance was set at a P-value <0.05.
Results

The clinical characteristics of the AHF patients are presented in Table 1. The contents of optimal medical therapy are described in Table 2. The clinical characteristics of healthy volunteers are shown in Table 3. The plasma aldosterone concentrations at 1 and 3 months after optimal therapy were statistically significantly elevated when compared to the concentration at baseline (120 ± 57 and 120 ± 58 pg/mL vs. 75 ± 41 pg/mL, respectively, P < 0.001). The plasma BNP concentrations at 1 and 3 months after optimal therapy were statistically significantly decreased when compared to the concentration at baseline (185 ± 156 and 143 ± 139 pg/mL vs. 682 ± 561 pg/mL, respectively, P < 0.001; Table 4. In the acute phase, the serum Ang-(1-7) concentration was statistically significantly lower and the serum ACE2 concentration was statistically significantly higher in heart failure patients than the healthy individuals (2.40 ± 1.11 vs. 3.10 ± 1.10 ng/mL, P < 0.005 and 7.45 ± 3.13 vs. 4.84 ± 2.25 ng/mL, P < 0.005, respectively; Figures 2 and 3). At 1 month after optimal therapy, the serum Ang-(1-7) concentration remained lower in heart failure patients than the healthy individuals (2.37 ± 1.63 vs. 3.10 ± 1.10 ng/mL, P < 0.05; Figure 1). However, there was no statistically significant difference in the serum ACE2 concentration between heart failure patients and the healthy individuals (6.11 ± 3.36 vs. 4.84 ± 2.25 ng/mL, P = 0.167; Figure 3). At 3 months after optimal therapy, there were no statistically significant differences in the serum Ang-(1-7) and ACE2 concentrations between heart failure patients and the healthy individuals (3.03 ± 2.07 vs. 3.10 ± 1.10 ng/mL, P = 0.854 and 6.10 ± 2.04 vs. 4.84 ± 2.25 ng/mL, P = 0.061, respectively; Figures 2 and 3).

Serial changes in the New York Heart Association (NYHA) classification are shown in Figure 4.
Discussion

In this study, all cases of decompensated heart failure with reduced EF were treated with optimal therapy following the appropriate guidelines [15], and they were all compensated along with a statistically significant decrease in the plasma BNP concentration.

We previously reported that acute decompensated heart failure patients had a statistically significantly higher serum ACE2 concentration and a statistically significantly lower serum Ang-(1-7) concentration when compared to the concentrations in healthy volunteers [13]. At 1 month after optimal therapy, there was no significant difference in the serum ACE2 concentration between heart failure patients and the healthy individuals. At 3 months after optimal therapy, the statistically significant difference in the serum Ang-(1-7) concentration between heart failure patients and the healthy individuals disappeared.

Although this study did not elucidate the mechanisms of the changes in ACE2 and Ang-(1-7) concentrations, it showed that the serum ACE2 concentration declined and the Ang-(1-7) concentration increased by optimal therapy in compensated heart failure cases, and as a result, both concentrations were equivalent to the healthy individuals. To our knowledge, this is the first study to report such findings.

It is well known that classical cascade in the RAS called the ACE/Ang II/Ang II type 1 receptor axis is a facilitating factor that promotes hypertension and damage to a variety of organs [1,2]. On the other hand, the existence of Ang-(1-7) was first reported in 1988 [16]. Crackower et al. reported in 2002 that ACE2 is involved in the development of heart failure in animal study [7]. Although the Ang-(1-7) receptor has
long been unknown, it was confirmed by Santos et al. in 2003 that the Mas receptor is the Ang-(1-7) receptor [8]. Based on these researches, it was shown that the ACE2/Ang-(1-7)/Mas receptor system maintains the mutual relationship by the action of Ang II mediated by Ang II type 1 receptor and has an action to antagonize the ACE/Ang II/Ang II type 1 receptor system [5,6]. Ang-(1-7) is produced from Ang I and Ang II catalyzed by ACE2. Ang II exerts actions such as vasoconstriction, inducing oxidative stress, cell hypertrophy, and fibrosis via Ang II type 1 receptor. Ang-(1–7) is known to exert antihypertensive and organ-protective effects via Mas receptor through vasodilation, reduction of oxidative stress, suppression of cell hypertrophy, anti-fibrotic action, natriuresis and anti-inflammation, it is known that the relationship between Mas receptor and Ang II type 1 receptors shows an antagonistic action like a seesaw mechanism [7-12].

A previous animal experiment showed that the ACE2 concentration increases if Ang II increases [17]. Ang-(1-7) has been shown to have a cardiovascular protective effect. Among the few studies that reported on the hypertensive or hypotensive effects induced by a decrease in the ACE2 concentration, Yamamoto et al. reported that ACE2 kinetics does not have a direct effect on blood pressure [18]. The results of this study suggest that Ang-(1-7), which has a cardiovascular protective effect, is insufficient in the decompensated heart failure stage, and its concentration increases with optimal therapy. Additionally, an increased ACE2 concentration is thought to decline to an optimal level, which is associated with sufficient Ang-(1-7).

Furthermore, a previous study reported that the Ang-(1-7) concentration increases according to ACE2 activity in human heart failure [19]; however, the Ang-(1-7) concentration increased during the compensation process of decompensated
heart failure in our study. The findings indicate that Ang-(1-7) is relatively insufficient in decompensated heart failure in the acute phase and the concentration increases along with compensation by optimal therapy.

These findings are very advanced results that favourably add to the further clarification of the mechanisms of the efficacy of the Ang II type 1 receptor blocker / neutral endopeptidase inhibitor combination [20], which has recently been approved for heart failure in Europe and the US.

In present study, 82% of patients were treated with ACE-inhibitor (ACE-i) or angiotensin receptor blocker (ARB). Therefore, it was expected that the plasma aldosterone concentration after discharge was lower than that at baseline. However, contrary to that expectation, plasma aldosterone concentrations increased after discharge, and the values at 1 and at 3 month after optimal therapy were similar. We observed a gradual increase in the plasma aldosterone concentration along with compensation of heart failure in this study. A previous study by Takeda et al. [21] reported that the circulating aldosterone concentration was inversely proportional to the myocardial tissue aldosterone concentration in an animal experiment. It can be assumed that a decrease in the myocardial tissue aldosterone concentration caused by compensation of heart failure was indirectly observed. In this study, 26% of patients were treated with mineralocorticoid receptor antagonists (MRA). It can be explained that MRA administration increased plasma aldosterone concentration in these patients. The mechanism of elevated plasma aldosterone levels in patients who did not receive MRA is difficult to explain. According to a report by Mizuno et al., aldosterone acts as a cardioprotective effect for a short period [22]. Therefore, it is considered that the concentration increases in the early phase of decompensated acute heart failure, and the
transition may be different for each patient due to the damage of myocardium when shifting to the chronic phase. However, there have been almost no reports to date that measured plasma aldosterone concentrations in patients with heart failure from the acute phase to the chronic phase. In addition, the reason for the increase in plasma aldosterone concentration after discharge in present study may be the effect of the aldosterone breakthrough phenomenon [23-25]. Specifically, after the RAS cascade is inhibited by ACE-i or ARB, the concentration of aldosterone at the most downstream of RAS is temporarily reduced. After that, the compensatory mechanism (details unknown) raises the aldosterone concentration again. It is considered that the aldosterone concentration changes similarly even when MRA is administered, and the aldosterone concentration increases because it does not bind to the mineralocorticoid receptor. Recently, it has been known that BNP has an action of suppressing the secretion of aldosterone from the adrenal gland [26]. The mechanism by which the suppression of aldosterone secretion is relieved by the reduction of BNP by compensating heart failure may also influence the increase in aldosterone levels. Moreover, there is also a report that administration of ACE-i or ARB increases the secretion of aldosterone via Ang II type 2 receptor [27], and our results may support this report. However, this cannot be affirmed only by the data of present study.

Further evidence from studies, including those involving animal experiments, is necessary as causal relationships between the kinetics of biomarkers in circulating blood and the concentrations of various biomarkers in tissue are unclear.

Finally, with recent pandemic of COVID-19, some concerns about the use of ACE-i and ARB have emerged in COVID-19 patients. ACE2 is the molecule used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for
COVID-19 pandemic to enter the cells [28-32]. Therefore, optimal medical treatment in heart failure, by reducing ACE2, will decrease the entrance of SARS-CoV-2 in the cells and thus mitigate the severity of the disease [33]. Contrary to initial reports by mass media that ACE-i/ARB might be deleterious in Covid-19, use of either may be associated with a lower risk of in-hospital death than nonuse.

Limitations of this study

The present study has some limitations. First, the study included limited number of diseased. Second, with regard to ACE2, the evaluation of activity rather than concentration might have allowed better and more direct understanding of the ACE2 effect; however, we could not obtain an ACE2 activity assay kit for this study. We consider that the ACE2 concentration should reflect ACE2 activity. Moreover, although ACE2 activity was not measured, we believe that measurement of the Ang-(1-7) concentration, which is a product of ACE2, supports the significance of this study. Third, in this study, we could not evaluate the effects of the drugs used for hospitalization treatment. Therefore, it is impossible to mention the effects on various parameters of drugs. Fourth, the patients were not treated with the modern SGLT2 inhibitors that have demonstrated to improve prognosis [34]. This is important because SGLT2 inhibitors mitigates this neurohormonal activation [35].

Conclusions

The serum ACE2 concentration was equivalent between AHF patients and the healthy individuals at 1 and 3 months after optimal therapy. Furthermore, the serum Ang-(1-7) concentration was equivalent between AHF patients and the healthy
individuals at 3 months after optimal therapy. In other words, it was observed that the increased serum ACE2 concentration gradually decreased to normal value, and the decreased serum Ang-(1-7) concentration gradually increased to normal value, in patients with acute decompensated heart failure with reduced LVEF, who were compensated after optimal medical therapy based on guideline.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

The authors declare that there are no sources of funding to be acknowledged.

Funding.

Author Contribution

S.H. was first investigator of this study. S.H., S.K., T.K., T.O., S.D. and T.F. collected data. S.H. wrote the manuscript. All authors reviewed and edited the manuscript. T.I. organized this study.

References

1. The Consensus Trial Study Group. (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1429-1435

2. The SOLVD Investigators. (1991) Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med.* **325**:293-302

3. Benedict, CR., Shelton, B., Johnstone, DE., Francis, G., Greenberg, B., Konstam, M. et al. (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. *Circulation.* **94**: 690-697

4. Güder, G., Bauersachs, J., Frantz, S., Weismann, D., Allolio, B., Ertl, G. et al. (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. *Circulation.* **115**:1754-1761, Epub 2007 Mar 19.

5. Santos, RA., Ferreira, AJ. and Simões e Silva, AC. (2008) Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. *Exp Physiol.* **93**: 519-527

6. Greenberg, B. (2008) An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. *J Am Coll Cardiol.* **52**:755-757

7. Crackower, MA., Sarao, R., Oudit, GY., Yagil, C., Koziaradzki, I., Scanga, SE. et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature.* **417**:822-828

8. Santos, RA., Simoes e Silva, AC., Maric, C., Silva, DM., Machado, RP., de Buhr, I.et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc Natl Acad Sci U S A.* **100**:8258-8263

9. Sasaki, S., Higashi, Y., Nakagawa, K., Matsuura, H., Kajiyama, G. and Oshima, T. (2001) Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. *Hypertension.* **38**:90-94
10. Ferreira, AJ., Santos, RA., Bradford, CN., Mecca, AP., Sumners, C., Katovich, MJ. et al. (2010) Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. *Hypertension*. 55:207-213

11. Rabelo, L.A., Alenina, N. and Bader, M. (2011) ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. *Hypertension Res.* 34:154-160

12. Horiuchi, M., Iwanami, J. and Mogi, M. (2012) Regulation of angiotensin II receptors beyond the classical pathway. *Clin Sci (Lond).* 123:193-203

13. Hisatake, S., Kiuchi, S., Kabuki, T., Oka, T., Dobashi, S. and Ikeda, T. (2017) Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization. *Heart Vessels.* 32:303-308

14. McKee, PA., Castelli, WP., McNamara, PM. and Kannel, WB. (1971) The natural history of congestive heart failure: the Framingham study. *N Engl J Med.* 285:1441-1446

15. JCS Joint Working Group. (2013) Guidelines for treatment of acute heart failure (JCS 2011). *Circ J.* 77:2157-2201, Epub 2013 Jun 12.

16. Schiavone, MT., Santos, RA., Brosnihan, KB., Khosla, MC. and Ferrario CM. (1988) Release of Vasopressin From the Rat Hypothalamo-Neurohypophysial System by angiotensin-(1-7) Heptapeptide. *Proc Natl Acad Sci U S A.* 85:4095-4098. doi: 10.1073/pnas.85.11.4095.

17. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J. et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem.* 277:14838-14843, Epub 2002 Jan 28.

18. Yamamoto, K., Ohishi, M., Katsuya, T., Ito, N., Ikushima, M., Kaibe, M. et al.
(2006) Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. *Hypertension.* **47:**718-726, Epub 2006 Feb 27.

19. Zisman, L.S., Keller, R.S., Weaver, B., Lin, Q., Speth, R., Bristow, M.R. et al. (2003) Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. *Circulation.* **108:**1707-1712, Epub 2003 Sep 22.

20. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M., Rizkala, A.R. et al. PARADIGM-HF Committees Investigators. (2014) Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). *Eur J Heart Fail.* **16:**817-825, doi: 10.1002/ejhf.115. Epub 2014 Jun 3.

21. Takeda, Y., Yoneda, T., Demura, M., Furukawa, K., Miyamori, I. and Mabuchi, H. (2001) Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. *J Hypertens.* **19:**635-639

22. Mizuno, Y., Yoshimura, M., Yasue, H., Sakamoto, T., Ogawa, H., Kugiyama, K. et al. (2001) Aldosterone production is activated in failing ventricle in humans. *Circulation.* **103:**72-77

23. Pitt, B. (1995) "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. *Cardiovasc Drugs Ther.* **9:**145-149

24. Staessen, J., Lijnen, P., Fagard, R., Verschueren, L.J. and Amery, A. (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. *J Endocrinol.* **91:**457-465
25. Cohn, JN., Anand, IS., Latini, R., Masson, S., Chiang, YT., and Glazer, R. (2003) Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. *Circulation*. **108**:1306-1309, Epub 2003 Aug 25.

26. Ito, T., Yoshimura, M., Nakamura, S., Nakayama, M., Shimasaki, Y., Harada, E. et al. (2003) Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. *Circulation*. **107**: 807-810

27. Tanabe, A., Naruse, M., Arai, K., Naruse, K., Yoshimoto, T., Seki, T. et al. (1998) Gene expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. *Horm Metab Res.* **30**:490-495

28. Zheng, YY., Ma, YT., Zhang, JY. and Xie, X. (2020) COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 10.1038/s41569-020-0360-5.

29. Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y. and Zhou, Q. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*. **367**:1444-1448

30. Hamming, I., Timens, W., Bulthuis, ML., Lely, AT., Navis, G and van Goor, H. (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* **203**:631-637

31. Vaduganathan, M VO., Michel, T., McMurray, JJV., Pfeffer, MA. and Solomon, SD. (2020) Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*. 10.1056/NEJMr2005760.

32. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S. et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. **181**:271-280 e8.
33. Mehra, MR., Desai, SS., Kuy, S., Henry, TD. and Patel, AN. (2020) Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med.* NEJMoa2007621. doi: 10.1056/NEJMoa2007621. Online ahead of print.

34. Flores, E., Santos-Gallego, CG., Diaz-Mejía, N. and Badimon, JJ. (2018) Do the SGLT-2 inhibitors offer more than hypoglycemic activity? *Cardiovasc Drugs Ther.* 32: 213-222, doi: 10.1007/s10557-018-6786-x.

35. Santos-Gallego, CG., Requena-Ibanez, JA., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B. et al. (2019) Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. *J Am Coll Cardiol.* 73: 1931-1944
Table legends

Table 1. Clinical characteristics of the acute heart failure patients

Table 2. Optimal medical therapy (continuous or discontinuous)

Table 3. Clinical characteristics of the healthy volunteers

Table 4. Serial changes in the plasma aldosterone concentration and plasma brain natriuretic peptide concentration
Figure legends

Figure 1
The molecular pathways of conventional ACE/angiotensin (Ang) II/Aldosterone and the novel ACE2/Ang-(1-7)
ACE2 was identified as a major Ang-(1-7)-forming enzyme. Ang I serves as a substrate for both ACE and ACE2. Ang II is known to have vasoconstrictor and fibrotic and hypertrophic effects in vivo. Both ACE and ACE2 are involved in the production of Ang-(1-7), which binds the Mas receptor and induces vasodilation and anti-fibrosis, anti-hypertrophy.
Abbreviations: ACE, angiotensin converting enzyme; AT, angiotensin II type ; NEP, neutral endopeptidase

Figure 2
Comparison of the serum angiotensin (Ang)-(1-7) concentration between patients and the reference value

Figure 3
Comparison of the serum angiotensin-converting enzyme (ACE)2 concentration between patients and the reference value

Figure 4
Serial changes in the NYHA classification
Abbreviations: NYHA, New York Heart Association
Figure 1. The molecular pathways of conventional ACE/angiotensin (Ang) II/Aldosterone and the novel ACE2/Ang-(1-7)
Figure 2. Comparison of the serum angiotensin (Ang)-(1-7) concentration (ng/ml) between patients and the reference value.
Figure 3. Comparison of the serum angiotensin-converting enzyme (ACE)2 concentration (ng/ml) between patients and the reference value.
Figure 4. Serial Changes in the NYHA Classification.
Table 1. **AHF patient clinical characteristics**

|                           | Patients with AHF |
|---------------------------|-------------------|
| **Number**                | 68                |
| **Age (years old)**       | 64±14             |
| **Sex (male/female)**     | 51/17             |
| **Height (cm)**           | 164±9             |
| **Body weight (kg)**      | 68±20             |
| **Body mass index**       | 25±6              |
| **Systolic blood pressure (mmHg)** | 119±24       |
| **Diastolic blood pressure (mmHg)** | 69±16         |
| **Left ventricular ejection fraction (%)** | 34±5          |
| **Cause of heart failure**|                   |
| Ischemic                  | 35 (51%)          |
| Non ischemic              | 33 (49%)          |
| **New York heart association class** |             |
| III                       | 30 (44%)          |
| IV                        | 38 (56%)          |

Medication before hospitalization
| Drug Type                                       | Frequency |
|-----------------------------------------------|-----------|
| ACE-i/ARB                                      | 19 (28%)  |
| Beta blockers                                  | 14 (21%)  |
| Loop diuretics                                 | 6 (9%)    |
| Mineralocorticoid receptor antagonists         | 5 (7%)    |
| Tolvaptan                                      | 1 (1%)    |
| Calcium channel blockers                       | 13 (19%)  |
| Nitrates                                       | 4 (6%)    |
| Carperitide                                    | 0 (0%)    |
| Inotropic agents                               | 2 (3%)    |
| Diabetes mellitus                              | 24 (35%)  |
| Lipid disorder                                 | 26 (38%)  |
| Smoking                                        | 29 (43%)  |
| Obesity (Body mass index > 25 (kg/m2))         | 23 (33%)  |
| BUN (mg/dl)                                    | 19 ±13    |
| Cr (mg/dl)                                     | 1.10±0.80 |
| e GFR (mL/min/1.73m2)                          | 64.1±24.5 |
| HbA1c (NGSP) (%)                               | 6.1±1.0   |
| TC (mg/dL)                                     | 170±42    |
|                       |       |
|-----------------------|-------|
| LDL-C (mg/dL)         | 106±34|
| HDL-C (mg/dL)         | 49±17 |
| LDL-C / HDL-C         | 2.36±0.95 |
| Triglyceride (mg/dL)  | 97±63 |

Data given as mean±SD or n (%).

AHF, acute heart failure; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BUN, blood urea nitrogen; Cr, creatinine; e GFR, estimated glomerular filtration; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol;
Table 2. **Optimal medical therapy (continuous or discontinuous)**

| Drug                              |        |
|-----------------------------------|--------|
| ACE-i/ARB                         | 56 (82%) |
| Beta blockers                     | 61 (90%) |
| Loop Diuretics                    | 38 (56%) |
| Mineralocorticoid receptor antagonists | 18 (26%) |
| Tolvaptan                         | 6 (9%)  |
| Calcium channel blockers          | 16 (24%) |
| Nitrates                          | 36 (53%) |
| Carperitide                       | 31 (46%) |
| Inotropic agents                  | 14 (21%) |

Data given as n (%).

ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
|                          | Healthy volunteers |
|--------------------------|--------------------|
| Number                   | 38                 |
| Age (years old)          | 47 ± 12            |
| Sex (male/female)        | 35/3               |
| Height (cm)              | 171 ± 6            |
| Body weight (kg)         | 67 ± 12            |
| Body mass index          | 23 ± 3             |
| Systolic blood pressure (mmHg) | 124 ± 74        |
| Diastolic blood pressure (mmHg) | 78 ± 10         |
| Concomitant drug         |                    |
| Calcium channel blocker  | 1 (3%)             |
| Beta blocker             | 1 (3%)             |
| Diuretics                | 0                  |
| Diabetes mellitus        | 0                  |
| Lipid disorder           | 3 (8%)             |
| Smoking                  | 4 (11%)            |
| Obesity (Body mass index > 25 (kg/m2)) | 5 (13%) |
| Test                  | Value         |
|----------------------|---------------|
| BUN (mg/dL)          | 13 ± 3        |
| Cr (mg/dL)           | 0.80 ± 0.11   |
| e GFR (ml/min/1.73m²)| 80.9 ± 13.3   |
| HbA1c (NGSP) (%)     | 5.4 ± 0.4     |
| TC (mg/dL)           | 201 ± 32      |
| LDL-C (mg/dL)        | 120 ± 32      |
| HDL-C (mg/dL)        | 66 ± 21       |
| LDL-C / HDL-C        | 2.03 ± 0.87   |
| Triglyceride (mg/dL) | 99 ± 50       |

Data given as mean±SD or n (%).

BUN, blood urea nitrogen; Cr, creatinine; e GFR, estimated glomerular filtration; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol;
Table 4. Serial changes in plasma aldosterone concentration and plasma BNP concentration

|                          | baseline | 1 month  | 3 month  | P value |
|--------------------------|----------|----------|----------|---------|
| Plasma aldosterone concentration (pg/mL) | 75±41    | 120±57*  | 120±58*  | <0.001  |
| Plasma BNP concentration (pg/mL)           | 682±561  | 185±156* | 143±139* | <0.001  |

Data given as mean±SD or n (%).

BNP, brain natriuretic peptide;

*, <0.001 (v.s. baseline):